Sanofi to sell surgical unit Seprafilm to Baxter for USD 350 million: Report

Sanofi took on Seprafilm, which is used to help manage the bleeding in abdominal and the pelvis operations, in 2011 as part of its purchase of Genzyme.

New Delhi: France's Sanofi has agreed to sell its Seprafilm unit, which makes specialist surgical products, to U.S.-based Baxter for $350 million euros, a source familiar with the matter said on Monday.

The French pharmaceutical group is conducting a broad a strategy review under new chief executive Paul Hudson, who will give some initial pointers on which businesses he wants to focus on at an investor day on Dec. 10.

Also Read: You cannot discontinue critical medicines without Prior Notice: NPPA tells Abbott, Bayer Zydus Pharma, Sanofi

Sanofi took on Seprafilm, which is used to help manage the bleeding in abdominal and the pelvis operations, in 2011 as part of its purchase of Genzyme.

Baxter officials were not immediately available to comment. A spokesman for Sanofi declined to comment.

Also Read: Landmark: Sanofi announces to reduce the price of TB drug Rifapentine by 70 per cent